Click on image to view larger version.

Figure 1 The In-Segment Restenosis Rate According to Drug-Eluting Stent and Use of Cilostazol

There is interaction between the type of drug-eluting stent and use of cilostazol for in-segment restenosis (p < 0.001). Although there was significant difference in relative measure of in-segment restenosis rate due to 0% in-segment restenosis rate of the sirolimus-eluting stent + cilostazol group, the absolute measure was not statistically different (p = 0.861).